World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application

SHANGHAI, May 9, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Investigational New Drug (IND) application for 9MW5211, its independently developed novel antibody, has received clearance from the U.S. Food... The post World’s First | Mabwell’s 9MW5211 Receives FDA Clearance for Clinical Trial Application appeared first on Kosmo Digital .

Go to News Site